Aurobindo Pharma’s injectable business achieves $50 million revenue in Q2

27 Dec 2018 Evaluate

Aurobindo Pharma’s injectable business unit -- AuroMedics has achieved a topline of $50 million in Q2 FY19, a growth of 8% as compared to corresponding quarter previous year. The company has filed a total of 104 injectables, abbreviated new drug applications (ANDAs), out of which 59 have received final approval and one tentative approval.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1217.45 -6.20 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×